Positive results obtained from in vitro studies designed to evaluate potential inhibitory effects of HRIG on SARS-CoV-2 entry and replication in human neuronal cell lines expressing the nAChR may provide putative proof of principle of our testable hypothesis and justify subsequent human clinical trials.